Literature DB >> 16547498

Telomere dysfunction and loss of p53 cooperate in defective mitotic segregation of chromosomes in cancer cells.

M Pantic1, S Zimmermann, H El Daly, O G Opitz, S Popp, P Boukamp, U M Martens.   

Abstract

Aneuploidy is a fundamental principle of many cancer cells and is mostly related to defects in mitotic segregation of chromosomes. Many solid tumors as well as some preneoplastic lesions have been shown to contain polyploid chromosome numbers. The exact mechanisms behind whole-genome duplications are not known but have been linked to compromised mitotic checkpoint genes. We now report that the telomere checkpoint plays a key role for polyploidy in colon cancer cells. Telomerase suppression by a dominant-negative mutant of hTERT and consecutive telomere dysfunction in wild-type HCT116 colon cancer cells resulted in only minor stable chromosomal alterations. However, higher ploidy levels with up to 350 chromosomes were found when the cell-cycle checkpoint proteins p53 or p21 were absent. These findings indicate that telomere dysfunction in the absence of cell-cycle control may explain the high frequency of alterations in chromosome numbers found in many solid tumors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16547498     DOI: 10.1038/sj.onc.1209486

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

1.  Persistent telomere damage induces bypass of mitosis and tetraploidy.

Authors:  Teresa Davoli; Eros Lazzerini Denchi; Titia de Lange
Journal:  Cell       Date:  2010-04-02       Impact factor: 41.582

2.  Molecular and cellular pathways associated with chromosome 1p deletions during colon carcinogenesis.

Authors:  Claire M Payne; Cheray Crowley-Skillicorn; Carol Bernstein; Hana Holubec; Harris Bernstein
Journal:  Clin Exp Gastroenterol       Date:  2011-05-03

Review 3.  Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins.

Authors:  Paula Martínez; María A Blasco
Journal:  Nat Rev Cancer       Date:  2011-03       Impact factor: 60.716

4.  Differences in telomerase activity between colon and rectal cancer.

Authors:  Georgios D Ayiomamitis; George Notas; Apostolos Zaravinos; Adamantia Zizi-Sermpetzoglou; Maria Georgiadou; Ourania Sfakianaki; Elias Kouroumallis
Journal:  Can J Surg       Date:  2014-06       Impact factor: 2.089

5.  The roles of telomerase in the generation of polyploidy during neoplastic cell growth.

Authors:  Agni Christodoulidou; Christina Raftopoulou; Maria Chiourea; George K Papaioannou; Hirotoshi Hoshiyama; Woodring E Wright; Jerry W Shay; Sarantis Gagos
Journal:  Neoplasia       Date:  2013-02       Impact factor: 5.715

6.  The epigenetic origin of aneuploidy.

Authors:  Luis A Herrera; Diddier Prada; Marco A Andonegui; Alfonso Dueñas-González
Journal:  Curr Genomics       Date:  2008-03       Impact factor: 2.236

7.  Progressive telomere dysfunction causes cytokinesis failure and leads to the accumulation of polyploid cells.

Authors:  Judit Pampalona; Cristina Frías; Anna Genescà; Laura Tusell
Journal:  PLoS Genet       Date:  2012-04-26       Impact factor: 5.917

8.  Glucose restriction decreases telomerase activity and enhances its inhibitor response on breast cancer cells: possible extra-telomerase role of BIBR 1532.

Authors:  Layal Wardi; Nada Alaaeddine; Issam Raad; Riad Sarkis; Rim Serhal; Charbel Khalil; George Hilal
Journal:  Cancer Cell Int       Date:  2014-07-04       Impact factor: 5.722

9.  Clinicopathological analysis of polyploid diffuse large B-cell lymphoma.

Authors:  Joji Shimono; Hiroaki Miyoshi; Junichi Kiyasu; Tomohiko Kamimura; Tetsuya Eto; Takuto Miyagishima; Koji Nagafuji; Masao Seto; Takanori Teshima; Koichi Ohshima
Journal:  PLoS One       Date:  2018-04-11       Impact factor: 3.240

10.  Telomere status in chronic lymphocytic leukemia with TP53 disruption.

Authors:  Romain Guièze; Mélanie Pages; Lauren Véronèse; Patricia Combes; Richard Lemal; Mathilde Gay-Bellile; Martine Chauvet; Mary Callanan; Fabrice Kwiatkowski; Bruno Pereira; Philippe Vago; Jacques-Olivier Bay; Olivier Tournilhac; Andreï Tchirkov
Journal:  Oncotarget       Date:  2016-08-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.